Literature DB >> 1321146

Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells.

R Seger1, N G Ahn, J Posada, E S Munar, A M Jensen, J A Cooper, M H Cobb, E G Krebs.   

Abstract

Two peaks of mitogen-activated protein (MAP) kinase activator activity are resolved upon ion exchange chromatography of cytosolic extracts from epidermal growth factor-stimulated A431 cells. Two forms of the activator (1 and 2) have been purified from these peaks, using chromatography on Q-Sepharose, heparin-agarose, hydroxylapatite, ATP-agarose, Sephacryl S-300, Mono S, and Mono Q. The two preparations each contained one major protein band with an apparent molecular mass of 46 or 45 kDa, respectively, on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Evidence identifying the MAP kinase activators as the 46- and 45-kDa proteins is presented. Using inactive mutants of MAP kinase as potential substrates, it was found that each preparation of MAP kinase activator catalyzes phosphorylation of the regulatory residues, threonine 188 and tyrosine 190, of Xenopus MAP kinase. These results support the concept that the MAP kinase activators are protein kinases. These MAP kinase kinases demonstrate an apparent high degree of specificity toward the native conformation of MAP kinase, although slow autophosphorylation on serine, threonine, and tyrosine residues and phosphorylation of myelin basic protein on serine and threonine residues is detected as well.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321146

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  86 in total

1.  A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission.

Authors:  A J Bardwell; L J Flatauer; K Matsukuma; J Thorner; L Bardwell
Journal:  J Biol Chem       Date:  2000-12-28       Impact factor: 5.157

2.  Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.

Authors:  S T Eblen; A D Catling; M C Assanah; M J Weber
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

3.  The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons.

Authors:  C A Singer; X A Figueroa-Masot; R H Batchelor; D M Dorsa
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

Review 4.  Signal control through Raf: in sickness and in health.

Authors:  Jihan K Osborne; Elma Zaganjor; Melanie H Cobb
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

5.  Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK.

Authors:  J L Swantek; M H Cobb; T D Geppert
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 6.  The ERK cascade: a prototype of MAPK signaling.

Authors:  Hadara Rubinfeld; Rony Seger
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

7.  Molecular cloning, expression, and characterization of the human mitogen-activated protein kinase p44erk1.

Authors:  D L Charest; G Mordret; K W Harder; F Jirik; S L Pelech
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

8.  Stimulation by phospholipids of a protein-tyrosine-phosphatase containing two src homology 2 domains.

Authors:  Z Zhao; S H Shen; E H Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Genetic analysis of the Caenorhabditis elegans MAP kinase gene mpk-1.

Authors:  M R Lackner; S K Kim
Journal:  Genetics       Date:  1998-09       Impact factor: 4.562

10.  Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes.

Authors:  R A Franklin; A Tordai; H Patel; A M Gardner; G L Johnson; E W Gelfand
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.